European Leukemia Trial Registry
Trial: ARD12042

More Details
Title Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
Scientific Title A Randomized Phase II, Open-Label Study of the Efficacy and Safety of Orally Administered SAR302503 in Patients With Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Who Are Resistant or Intolerant to Hydroxyurea
Short Title ARD12042
Trialgroup NN
Type of Trial randomized, open-label
Disease Myeloproliferative disease(MPD) Polycythaemia vera
Myeloproliferative disease(MPD) Essential Thrombocythaemia
Age >= 18 years
Status Active
Start of Recruitment 01.04.2012
Leader Hochhaus, Prof. Dr. med., Andreas
Shortprotocol Shortprotocol
created 01.10.2012 Sina Hehn
changed 08.05.2013 Sina Hehn
ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org